Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban vs Apixaban for Brain Lesions in Stroke with Atrial Fibrillation
NCT06864052Not yet recruiting
- Sponsor
- Ewha Womans University Seoul Hospital
- Start
- Mar 2025
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of apixaban in ischemic stroke and Atrial fibrillation (AFib) (2 arms), sponsored by Ewha Womans University Seoul Hospital. Primary endpoint: Incidence of new brain lesions on Brain MRI at 24 months. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
apixaban
03
Conditions
ischemic strokeAtrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06864052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864052.